Zacks Investment Research on MSN
Vertex Plunges Around 24% in Six Months: How to Play the Stock
Vertex Pharmaceuticals Incorporated VRTX stock has declined 23.6% in the past six months, mainly due to recent pipeline setbacks. In August 2025, Vertex’s phase II study on the oral formulation of ...
From shocking outliers to budget-friendly powerhouses, we've learned which cordless vacuums truly excel in battery life, according to CNET’s rigorous testing.
The Railway Protection Force (RPF) has officially released the zone-wise vacancy details for the post of Sub Inspector (Executive) under recruitment notification CEN RPF-01/2024. A total of 452 ...
Daniel Liberto is a journalist with over 10 years of experience working with publications such as the Financial Times, The Independent, and Investors Chronicle. Erika Rasure is globally-recognized as ...
Missense variants in the O-GlcNAc transferase ( OGT) gene have recently been shown to segregate with a syndromic form of intellectual disability (OGT-ID), underscoring the importance of protein ...
Scientists have shown that two previously separate modes of plant branching regulation can be connected, revealing the most ...
Scientists have uncovered how the plant hormone auxin helps roots bend and downwards towards gravity—a process called ...
Vertex Pharmaceuticals (VRTX) has outperformed the market over the past 15 years by 4.73% on an annualized basis producing an average annual return of 17.22%. Currently, Vertex Pharmaceuticals has a ...
Jupiter Endovascular announced today that its Vertex catheter received FDA 510(k) clearance for the insertion of endovascular ...
Vertex Pharmaceuticals has a lot of buy and hold ratings, but there aren't any sell ratings from Wall Street analysts. Around ...
At this grand event focusing on the deep integration of technology and innovation, Xu Yihan, Senior Executive Vice President ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results